Alvotech at UBS biopharma conference: pipeline, launches and scale
At the UBS Global Biopharma Conference 2026, Alvotech (ALVO) highlighted its entry into a significant growth phase, buoyed by a robust pipeline of in-house biosimilars, escalating commercial sales, and upcoming regulatory milestones. The management emphasized the company's diversifying operating model, acknowledging risks such as patent disputes and the necessity to augment supply capacities.
Alvotech disclosed roughly 30 biosimilar products currently under development, positioning itself at a pivotal juncture. The company's third-quarter 2024 revenue amounted to $110 million, with EBITDA reaching $31 million, and anticipates a record fourth quarter propelled by December stockpiling activities.
Upcoming FDA decisions on December 4, 2024, will cover SIMPONI, low-dose EYLEA, and XGEVA biosimilars. Alvotech is bolstering its supply chain through strategic partnerships with Lotte and Fujifilm, aiming for drug substance delivery in late 2025 and finished products by the first quarter of 2028. The biosimilar market, the management noted, is becoming increasingly concentrated, with fewer entities capable of managing complete development and production.
Founded in 2013, Alvotech has invested over $2 billion in research, development, and manufacturing infrastructure, adopting a vertical integration model that encompasses drug substance development, fill-finish operations, and auto-injector assembly.
The company collaborates with 20 commercial partners, including Teva in the U.S. and Advanz and STADA in Europe, and forecasts continued business growth through 2027 as new products launch and existing ones expand market share. In a Q&A session, management argued that despite the presence of more than 200 biosimilar companies globally, only a select few can manage end-to-end development and manufacturing due to substantial capital investments and approximately a ten-year development timeline.
Alvotech reported robust third-quarter 2024 results, with $110 million in revenue and $31 million in EBITDA, projecting a record fourth quarter driven by December stockpiling. The company detailed its milestone-based business model, featuring payments at signing and additional milestones tied to development, clinical progress, submission, and approval, maintaining confidence in its previously stated earnings outlook.
On product economics, Alvotech mentioned that developing the HUMIRA biosimilar to approval costed more than $300 million, including interchangeability status, with per-product development costs typically ranging from $50 million to $100 million. Oncology products generally incur higher costs due to the necessity for real patient studies.
The company's revenue over the past year reached $492 million, with EBITDA of $89 million, showcasing the scale of its commercial operations. Despite a significant debt burden of $1.56 billion, Alvotech's stock is perceived as undervalued based on Fair Value calculations. Management highlighted several products gaining traction, such as the HUMIRA biosimilar, which holds the second-best market share in the U.S., with conversion rates above 60% by mid-2024.
The European SIMPONI launch, initiated with Advanz, has been successful, securing a 25% market share since its release.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.